Search Results - "Toyos, Melissa M"

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification by Toyos, Melissa M.

“…Aim Randomized pilot study comparing clinical outcomes with bromfenac ophthalmic solution 0.07% versus nepafenac 0.3% ophthalmic suspension administered as…”
Get full text

Letter to the Editor Re “Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction” by Toyos, Melissa M

Get full text

Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study by Sheppard, John D, Toyos, Melissa M, Kempen, John H, Kaur, Paramjit, Foster, C Stephen

“…Endogenous anterior uveitis (AU), when untreated, may lead to vision loss. This study compared the safety and efficacy of difluprednate versus prednisolone…”
Get full text

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease by Tauber, Joseph, Schechter, Barry A, Bacharach, Jason, Toyos, Melissa M, Smyth-Medina, Robert, Weiss, Sidney L, Luchs, Jodi I

“…The aim of this study was to evaluate the safety and efficacy of OTX-101, a clear nanomicellar aqueous solution of cyclosporine, in the treatment of dry eye…”
Get full text

Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies by Sheppard, John D., Foster, C. Stephen, Toyos, Melissa M., Markwardt, Kerry, Da Vanzo, Robert, Flynn, Thomas E., Kempen, John H.

“…Purpose: To analyse pooled data from 2 similar phase 3 noninferiority studies comparing difluprednate 0.05% versus prednisolone acetate 1% in patients with…”
Get full text

Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study by Pasquali, Theodore A, Toyos, Melissa M, Abrams, David B, Scales, David K, Seaman, 3rd, John W, Weissgerber, Georges

“…Licaminlimab is a new anti-TNFα antibody fragment for topical ocular application. This phase II study assessed the tolerability, treatment effect, and…”
Get full text

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial by Nichols, Kelly K, Holland, Edward, Toyos, Melissa M, Peace, James H, Majmudar, Parag, Raychaudhuri, Aparna, Hamdani, Mohamed, Roy, Monica, Shojaei, Amir

“…To evaluate ocular comfort of lifitegrast ophthalmic solution 5.0% among patients with dry eye disease (DED) in the OPUS-3 trial. OPUS-3 was a multicenter,…”
Get full text

Letter to the Editor Re “Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction” by Toyos, Melissa M.

Get full text

Ocular comfort assessment of liftegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial by Nichols, Kelly K, Holland, Edward, Toyos, Melissa M, Peace, James H, Majmudar, Parag, Raychaudhuri, Aparna, Hamdani, Mohamed, Roy, Monica, Shojaei, Amir

“…Purpose: To evaluate ocular comfort of lifitegrast ophthalmic solution 5.0% among patients with dry eye disease (DED) in the OPUS-3 trial. Methods: OPUS-3 was…”
Get full text

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] by Tauber, Joseph, Schechter, Barry A, Bacharach, Jason, Toyos, Melissa M, Smyth-Medina, Robert, Weiss, Sidney L, Luchs, Jodi I

“…Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol.2018;12:1921-1929.On page 1927, "Safety and tolerability assessments" section,third paragraph,…”
Get full text

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum] by Nichols, Kelly, Holland, Edward, Toyos, Melissa M, Peace, James, Majmudar, Parag, Raychaudhuri, Aparna, Hamdani, Mohamed, Roy, Monica, Shojaei, Amir

“…Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial…”
Get full text

A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum] by Tauber, Joseph, Schechter, Barry A, Bacharach, Jason, Toyos, Melissa M, Smyth-Medina, Robert, Weiss, Sidney L, Luchs, Jodi I

“…Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921-1929.On page 1924, Efficacy end points, Conjunctival staining section, the sentence…”
Get full text

Clinical and patient-reported outcomes of bilateral implantation of a +2.5 diopter multifocal intraocular lens by Maxwell, Andrew, MD, PhD, Holland, Edward, MD, Cibik, Lisa, MD, Fakadej, Anna, MD, Foster, Gary, MD, Grosinger, Les, MD, Moyes, Andrew, MD, Nielsen, Stephen, MD, Silverstein, Steven, MD, Toyos, Melissa, MD, Weinstein, Arthur, MD, Hartzell, Scott, MD

“…Purpose To assess the effectiveness and safety of a multifocal intraocular lens (IOL) with +2.5 diopter (D) additional power compared with a monofocal IOL…”
Get full text